Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Aikaterini Markopoulou

Neurology Glenview, IL Medical Doctor

NPI 1568758696 CMS profile 1148417

2100 Pfingsten Rd, Glenview, IL 60026

Open in the dashboard

General payments

$3,456

39 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$37,958 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Aikaterini Markopoulou of Glenview, IL is reported in the CMS Open Payments database as having received $3,456 across 39 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $37,958 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 61st percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $366 5
2024 General $1,194 22
2023 General $1,145 6
2022 General $72 2
2021 General $103 1
2020 General $420 1
2019 General $156 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aikaterini Markopoulou
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Aikaterini Markopoulou were reported at $366. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Aikaterini Markopoulou Neurology median Middle half National median
2019 $156 $474 $118–$2,177 $163
2020 $420 $367 $82–$2,309 $114
2021 $103 $438 $104–$2,547 $132
2022 $72 $442 $103–$2,388 $149
2023 $1,145 $464 $119–$2,312 $160
2024 $1,194 $468 $119–$2,323 $164
2025 $366 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $1,863 30 payments
  2. Boston Scientific Corporation $1,077 5 payments
  3. Medtronic USA, Inc. $444 2 payments
  4. Illumina, Inc. $47 1 payment
  5. Ge Healthcare $24 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,590 27 payments
  2. Travel and Lodging $1,446 11 payments
  3. Consulting Fee $420 1 payment
Products named General payments · program years 2019–2025
  1. Vercise $842 3 payments
  2. PERCEPT PC BRAINSENSE $681 15 payments
  3. ACTIVA $420 1 payment
  4. ACTIVA PC $134 1 payment
  5. GENERAL DBS Dbs $131 1 payment
  6. GENERAL DBS Pain Management $103 1 payment
  7. NovaSeq 6000Dx Sequencer Instrument $47 1 payment
  8. SenSight $46 3 payments
  9. MazorX - Renaissance $24 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

3,211

Median for Neurology: 833

Drug cost

$610,626

Median for Neurology: $202,670

Branded share of claims

53.4%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 20 $171,825
Rytary Carbidopa/Levodopa Brand 181 $167,311
Nuplazid Pimavanserin Tartrate Brand 16 $96,938
Droxidopa Generic 79 $56,267
Carbidopa-Levodopa Carbidopa/Levodopa Brand 761 $28,534
Myrbetriq Mirabegron Brand 15 $14,168
Carbidopa-Levodopa Er Carbidopa/Levodopa Brand 298 $12,423
Pramipexole Er Pramipexole Di-Hcl Brand 15 $6,503
Rivastigmine Rivastigmine Tartrate Brand 77 $6,186
Entacapone Generic 21 $4,640

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$77,685

Medicare's payments for the services billed

Medicare patients

302

Average age 77

Services billed

1,052

144 women, 158 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 62%
Arthritis 54%
Depression 39%
Diabetes 27%
Ischemic heart disease 27%
Osteoporosis 24%
Alzheimer's or dementia 21%
Heart failure 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

39 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record